The New York State Department of Health identified 42 drugs from 25 manufacturers for possible referral to the state's Drug Utilization Review (DUR) board. The DoH will immediately begin negotiating with manufacturers supplemental rebates for prescriptions covered under Medicaid, which the manufacturers would have to concede in addition to the automatic discount to the drug's list price afforded to state Medicaid programs under federal law.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,